In fact by switching from the CAG promoter to an endogenous Neuronal Specific Enolase promoter (NSE), we very significantly improved expression of therapeutic ZF molecules over time in the CNS of HD mouse models and were able to observe the therapeutic effect up to 6 months post single injection (Agustin-Pavon et al., 2016). This evidence concerns the gene ENO2 and Huntington disease.